Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-645-2615
Dr. Zhang is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Tian Zhang is an oncologist in Dallas, TX and is affiliated with UT Southwestern Medical Center. She received her medical degree from Harvard Medical School and has been in practice 14 years. She speaks multiple languages, including Chinese (Mandarin). She specializes in genitourinary cancers with experience in treatment of prostate, renal, bladder, and testicular cancers.
Education & Training
University of Texas Health Science Center at HoustonResidency, Gastroenterology, 2016 - 2022
Duke University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015- Duke University HospitalResidency, Internal Medicine, 2010 - 2012
- Duke University HospitalInternship, Internal Medicine, 2009 - 2010
Harvard Medical SchoolClass of 2009
Certifications & Licensure
NC State Medical License 2009 - 2027
TX State Medical License 2021 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
Clinical Trials
- Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) Start of enrollment: 2014 Mar 01
- Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer Start of enrollment: 2015 Apr 01
- Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO Start of enrollment: 2019 Nov 01
Publications & Presentations
PubMed
- Stereotactic Ablative Radiation Therapy for Oligoprogressive Metastatic RCC: Predictors of Prolonged Benefit from Ongoing Systemic Therapy.Lucian Zhao, Dana Keilty, Soumyajit Roy, Tidie Song, Aurelie Garant
International Journal of Radiation Oncology, Biology, Physics. 2026-08-01 - Differential Tumor Response Patterns and Extent of Necrosis After Immunotherapy Combinations Predict Clinical Responses for Renal Cell Carcinoma.Wadih Issa, Nicolas Sayegh, Damla Gunenc, Navneet Kaur, Andrew DeVilbiss
Clinical Genitourinary Cancer. 2026-06-01 - Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer.Chuan Angel Lu, Changchuan Jiang, Andrew Z Wang, Tian Zhang
JAMA Network Open. 2026-05-01
Abstracts/Posters
- Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2Tian Y Zhang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after ra...2019 ASCO Annual Meeting - 6/1/2019
- PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (All...2019 ASCO Annual Meeting - 6/1/2019
- Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Alliance Webinar Showcases Cutting-Edge Advances in Cancer TreatmentSeptember 16th, 2025- Frontline Nivolumab Combination Maintains Superiority Over Sunitinib in Kidney CancerFebruary 19th, 2025
COVID-19 Vaccines for Patients with Cancer: Benefits Likely Outweigh RisksFebruary 27th, 2021
Professional Memberships
- Associate
- Member
- Member
- Member
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
